权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Antitumor Effect of Spleen in Immunochemotherapy after gastrectomy for gastric cancer.

脾脏在胃癌胃切除术后免疫化疗中的抗肿瘤作用。

基本信息

批准号：
04670771
负责人：
SEKIKAWA Takayoshi
金额：
$ 1.02万
依托单位：
Yamanashi Medical University
依托单位国家：
日本
项目类别：
Grant-in-Aid for General Scientific Research (C)
财政年份：
1992
资助国家：
日本
起止时间：
1992 至 1993
项目状态：
已结题

项目摘要

The growth of syngenic COLON 26 tumor ells inoculated in the abdominal s.c. of BALB/c mouse was depressed by injection of OK-432 into the growing tumor. The tumor growth inoculated in the abdominal s.c.and treated by combination therapy with OK-432 and cycolphosphamide(CY) was significantly smaller than treated by either OK-432 or CY.In the combination therapy group, %L3T4 was increased as that of CY group. And only in the combinationtherapy grouop, %L3T4 of spleen cells was significantly increased. Spleen cells of combination therapy group hadin vivo tumor neutralizing activity, though it was weaker than that of the OK-432 group.The aim of second experiment as to examine whether the spleenhad really effective immune activity on immunochemotherapy. In the combination therapy group, splenetomy was undertaken 6hrs or 12 hrs later after administration of OK-432 and CY.The tumorgrowth was smaller in the 12hrs group than in the 6hrs group.These data suggested the spleen had effective immune activity in the combination therapy with OK-432 and CY.The retrospectivestudy was undertaken to gain insight into the relationship between spleen and immunochemotherapy after total gastrectomy. The patients were stratified into two groupsin stage II and III : a splenectomized group and a spleen preserved group. Further-more the patients in each group were divided into immunotherapy group and non-immunotherapy group. Survivals of the splenectomized group waslower than spleen preserving group. The 5-year survival rate of the spleen preserved group with immunotherapy in stage III was 41.7%. It was significantly higher level compared with 0% of splenectomized group with nonimmunotherapy in stage III.These results suggest that the spleen is necessaryfor effective immunotherapy.

腹腔接种同系结肠26肿瘤细胞的生长。瘤体内注射OK-432可明显抑制BALB/c小鼠肿瘤生长。OK-432与环磷酰胺（CY）联合治疗组的肿瘤生长明显小于单用OK-432或CY治疗组，联合治疗组的%L_3T_4与CY治疗组一样升高。仅联合治疗组脾细胞%L3T4显著升高。联合治疗组脾细胞具有体内肿瘤中和活性，但弱于OK-432组。第二个实验的目的是检验脾细胞是否具有对免疫化疗真正有效的免疫活性。在联合治疗组中，OK-432和CY联合治疗后6小时或12小时行脾切除术，12小时组肿瘤生长小于6小时组，提示OK-432和CY联合治疗对脾有有效的免疫活性。432和CY的免疫化疗的关系进行了回顾性研究，以了解脾脏和免疫化疗的关系。将II期和III期患者分为两组：脾切除组和脾保留组。并将各组患者分为免疫治疗组和非免疫治疗组。脾切除组生存率低于保脾组。Ⅲ期免疫治疗保脾组5年生存率为41.7%。与未行免疫治疗的脾切除组相比，Ⅲ期脾切除组有显著性增高，提示脾是有效免疫治疗的必要部位。